行情

MRKR

MRKR

TAPIMMUNE
NASDAQ

实时行情|Nasdaq Last Sale

4.160
-0.190
-4.37%
盘后: 4.160 0 0.00% 16:52 10/18 EDT
开盘
4.310
昨收
4.350
最高
4.400
最低
4.100
成交量
23.64万
成交额
--
52周最高
10.25
52周最低
3.970
市值
1.90亿
市盈率(TTM)
-1.0565
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

MRKR 新闻

  • "超级星期六"失败后 约翰逊坚持:绝不再协商推迟脱欧
  • 新浪美股.3小时前
  • 瑞信将负利率转嫁至富人 最高征收每年0.85%的保管费
  • 新浪美股.5小时前
  • AI芯片持久战:是好故事,但不是好生意?
  • 钛媒体.6小时前
  • 中日独角兽数量96:3 日本为何成不了创业热土?
  • 虎嗅APP.7小时前

更多

所属板块

生物技术和医学研究
-1.17%
制药与医学研究
-0.94%

热门股票

名称
价格
涨跌幅

MRKR 简况

Marker Therapeutics, Inc., formerly TapImmune Inc., is an immuno-oncology company. The Company specializes in the development of peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer. It is engaged in developing vaccines that target candidate breast cancers, colorectal cancers, ovarian cancers and non-small cell lung cancers. It combines a set of licensed technologies, including peptide antigen technologies and deoxyribonucleic acid (DNA) expression technologies that improve the ability of the cellular immune system to recognize and destroy diseased cells. Its core technology platforms include TPIV 100/110, a vaccine for the treatment of Human Epidermal Growth Factor receptor 2 (HER2)/neu+ breast cancer that over-expresses HER2/neu; TPIV 200, a vaccine for treating breast and ovarian cancers that over-express Folate Receptor Alpha, and DNA expression vaccine technology (Polystart) for further treating various cancers or infectious disease.
展开

Webull提供Marker Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。